Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program
Raffaele Campisi(University of Catania), Nunzio Crimi(University of Catania), Maria Pia Foschino Barbaro(University of Foggia), Gabriella Guarnieri(Mylan (Switzerland)), Giulia Scioscia(University of Foggia), Claudia Crimi(Marconi University), Alberto Papi(University of Ferrara), Santi Nolasco(University of Catania), Bianca Beghé(Azienda Ospedaliero-Universitaria di Modena), Leonardo Antonicelli(Ospedali Riuniti di Ancona), Luigi Macchia(University of Bari Aldo Moro), Morena Porto(University of Catania), Nicola Scichilone
Cited by 63
Related Papers
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
|European Respiratory Journal|2017|679
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
|Cochrane Database of Systematic Reviews|2017|648
Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis
|The Lancet Infectious Diseases|2017|473
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
|New England Journal of Medicine|2023|452
Benralizumab for the Prevention of COPD Exacerbations
|New England Journal of Medicine|2019|329